Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	5.14	4.62	0
Cash & Short-Term Investments	5.14	4.62	0
Cash Growth	11.30%	230950.00%	-
Other Current Assets	0.03	0.38	2.31
Total Current Assets	5.17	5	2.32
Total Assets	5.17	5	2.32
Accounts Payable	0.56	0.2	0.82
Accrued Expenses	0.04	0.09	0.09
Short-Term Debt	-	-	0.13
Total Current Liabilities	0.61	0.29	1.04
Total Liabilities	0.61	0.29	1.04
Common Stock	0.01	0	0
Additional Paid-in Capital	104.2	95.36	61.57
Retained Earnings	-99.64	-90.65	-60.29
Shareholders' Equity	4.57	4.71	1.28
Total Liabilities & Equity	5.17	5	2.32

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q